Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expanded ...
Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI ® ” (brand name in China: “??? ® ”, ...
Hubert Dodds is currently an in-patient in Newcastle, but his family want him closer to home.
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and ...
New digital health platform being launched in partnership with UCSD allows remote physician-monitored neurotherapy ...
Two Gold Coast patients have become the first in Queensland to receive new medications which doctors hope may offer a better ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...
Stockholm, Sweden Tuesday, February 10, 2026, 14:00 Hrs [IST] ...
Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril ...
Unlike general therapy centers, Thera Physical Therapy is part of an active movement to bring quality healthcare to the forefront of medicine. The team believes that every part of the body deserves ...
Divergent diagnostic criteria is raising concerns that some patients are being misdiagnosed and unnecessarily treated.
Bliss, a Ph.D. student at UC Berkeley, typically gets up at 6 a.m. to make the drive to rural Lake County, where she’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results